Profile data is unavailable for this security.
About the company
Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.
- Revenue in CNY (TTM)6.43bn
- Net income in CNY523.43m
- Incorporated1993
- Employees8.41k
- LocationZhejiang CONBA Pharmaceutical Co LtdBinjiang Technological & Economc PrkNo.568 Bnkng Rd,Hi-Tech Development ZoneHANGZHOU 310052ChinaCHN
- Phone+86 57 187774288
- Fax+86 57 187774722
- Websitehttp://www.conbapharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 10.40bn | 2.55k | 20.27 | 1.32 | -- | 3.81 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Tibet Rhodiola Pharmaceutical Holding Co | 2.93bn | 810.63m | 10.58bn | 601.00 | 11.70 | 2.22 | -- | 3.61 | 2.81 | 2.81 | 9.65 | 14.76 | 0.6016 | 1.81 | 6.68 | 4,877,892.00 | 16.83 | 12.44 | 23.18 | 15.71 | 93.68 | 90.51 | 27.97 | 20.43 | 2.79 | 7.96 | 0.1716 | 50.41 | 22.69 | 24.98 | 116.56 | 30.01 | -1.48 | 48.97 |
| Zhejiang Medicine Co., Ltd. | 8.04bn | 425.74m | 10.64bn | 6.23k | 24.75 | 1.09 | -- | 1.32 | 0.447 | 0.447 | 8.41 | 10.13 | 0.6329 | 2.91 | 5.57 | 1,290,409.00 | 2.14 | 4.32 | 2.75 | 5.68 | 31.16 | 36.57 | 3.39 | 6.28 | 1.62 | 5.95 | 0.0819 | 58.72 | -3.96 | 2.59 | -20.37 | 3.34 | 12.65 | 0.00 |
| Aurisco Pharmaceutical Co Ltd | 1.30bn | 325.73m | 10.87bn | 1.52k | 33.34 | 5.23 | -- | 8.39 | 0.803 | 0.803 | 3.18 | 5.12 | 0.5404 | 1.17 | 4.99 | 852,082.90 | 13.57 | 12.40 | 16.46 | 14.33 | 56.90 | 51.26 | 25.12 | 23.05 | 1.72 | -- | 0.116 | 25.15 | 25.24 | 17.02 | 37.23 | 16.16 | 26.54 | -- |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 1.80bn | 514.80m | 11.20bn | 2.47k | 21.75 | 2.57 | -- | 6.23 | 1.18 | 1.18 | 4.11 | 9.95 | 0.36 | 2.68 | 6.66 | 727,792.60 | 10.31 | -- | 11.11 | -- | 39.78 | -- | 28.63 | -- | 5.51 | -- | 0.0551 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.43bn | 523.43m | 11.54bn | 8.41k | 22.22 | 1.62 | -- | 1.80 | 0.202 | 0.202 | 2.49 | 2.78 | 0.5568 | 2.39 | 4.60 | 764,058.90 | 5.02 | 6.77 | 7.25 | 10.50 | 54.36 | 63.24 | 9.02 | 11.10 | 1.53 | 40.71 | 0.1459 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
| Mayinglong Pharmaceutical Group Co Ltd | 3.26bn | 453.31m | 11.55bn | 2.88k | 25.48 | 2.95 | -- | 3.54 | 1.05 | 1.05 | 7.56 | 9.08 | 0.6482 | 5.87 | 11.13 | 1,130,851.00 | 9.26 | 10.82 | 11.03 | 13.47 | 42.87 | 41.18 | 14.29 | 14.08 | 5.18 | -- | 0.0729 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 5.25bn | 989.32m | 12.10bn | 4.88k | 12.19 | 1.39 | -- | 2.31 | 1.10 | 1.10 | 5.84 | 9.69 | 0.4523 | 1.87 | 4.36 | 1,076,055.00 | 8.52 | 10.10 | 11.07 | 13.69 | 35.80 | 34.64 | 18.83 | 16.26 | 2.07 | -- | 0.1816 | 40.79 | 1.44 | 24.29 | 12.20 | 45.74 | 32.14 | 20.11 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.07bn | 352.22m | 12.19bn | 965.00 | 34.60 | 2.44 | -- | 11.35 | 0.571 | 0.571 | 1.74 | 8.09 | 0.2078 | 1.14 | 9.25 | 1,112,527.00 | 6.61 | 1.32 | 6.93 | 1.41 | 77.85 | 80.74 | 31.81 | 6.55 | 6.66 | -- | 0.01 | 8.25 | 22.84 | -2.35 | 497.63 | -4.44 | 21.22 | -- |
Data as of Jul 05 2024. Currency figures normalised to Zhejiang CONBA Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
7.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kuwait Investment Authority (Investment Management)as of 30 Sep 2023 | 41.34m | 1.61% |
| First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 38.76m | 1.51% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 24.50m | 0.96% |
| ABC-CA Fund Management Co., Ltd.as of 31 Dec 2023 | 17.05m | 0.67% |
| CIB Fund Management Co., Ltd.as of 31 Dec 2023 | 13.36m | 0.52% |
| Founder Fubon Fund Management Co., Ltd.as of 31 Dec 2023 | 11.16m | 0.44% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 9.80m | 0.38% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 9.28m | 0.36% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 8.62m | 0.34% |
| The Vanguard Group, Inc.as of 31 May 2024 | 6.29m | 0.25% |
More ▼
Data from 31 Dec 2023 - 01 Jul 2024Source: FactSet Research Systems Inc.
